
Cartoon – New Miracle Drug



— 2020 drug price increases unlikely to catalyze cost-cutting action, say experts.
Both House Speaker Nancy Pelosi and Republican Sen. Chuck Grassley cited the initial wave of drug price hikes as examples of why their respective bills tackling the cost of pharmaceuticals should move forward. But when Prescription PULSE spoke with a half dozen experts tracking the industry, not one believed the hikes — which averaged around 5 percent across more than 470 drugs — would sway Congress or the administration to drug pricing reform.
“The increases are a persistent reminder that Congress and the administration have done nothing to reduce drug prices. But the increases also happen so regularly that it’s probably unrealistic to think they’ll spur any action this time around,” said Rob Smith, who tracks the political and policy outlook of the drug industry for Capital Alpha Partners.
“I don’t necessarily think the increases themselves improve or diminish the odds of material drug pricing legislation getting across the finish line,” said John Leppard of Washington Analysis.
Of the 471 drugs whose prices have increased, 466 were brand-name medicines, according to GoodRx, which tracks where consumers can get lower-priced medicines. GoodRx doesn’t track doctor-administered drugs so there were likely other increases not captured by their analysis. Other companies are expected to announce price increases as the month goes on.
Despite the focus on drug costs, companies are continuing their habit of regularly raising the prices, often multiple times a year, said Anna Kaltenboeck, a program director and senior health economist at Memorial Sloan Kettering Cancer Center. “This is the starting volley for the year so to speak,” she said.

The suit alleges Omnicare, the nation’s largest long-term care pharmacy, kept dispensing antipsychotics, anticonvulsants, antidepressants and other drugs based off invalid prescriptions for months, and sometimes years, without obtaining fresh scripts from patients’ doctors.
Managers at the long-term care business allegedly ignored prescription refill limitations and expiration dates and forced staff to fill prescriptions quickly, pressuring some facilities to process and dispense thousands of orders daily. When prescriptions expired, Omnicare “rolled over” the scripts, assigning them a new number, allowing the pharmacy to dispense the drug indefinitely without need for doctor involvement.
This practice allowed Omnicare to continually dispenses drugs for seniors and disabled occupants in more than 3,000 residential long-term care facilities, at an ongoing risk to their health, according to DOJ. Many of the prescription drugs were meant to treat serious conditions like dementia, depression or heart disease and have side effects when not closely monitored by a physician — particularly when taken in tandem with other medications.
The pharmacy then submitted knowingly false claims to Medicare, Medicaid and TRICARE, which serves military personnel, for the illegally dispensed drugs over an eight-year period; and lied to the government about the status of the prescriptions. CVS Health senior management was also aware of the scheme, according to DOJ.
“A pharmacy’s fundamental obligation is to ensure that drugs are dispensed only under the supervision of treating doctors who monitor patients’ drug therapies,” Manhattan U.S. Attorney Geoffrey Berman said in a statement. “Omnicare blatantly ignored this obligation in favor drugs out the door as quickly as possible to make more money.”
The government joined the lawsuit originally brought by Uri Bassan, an Albuquerque, New Mexico pharmacist for Omnicare, filed in June 2015. The original whistleblower suit said Omnicare’s compliance department was aware of the “rolling over” process, but did nothing to stop it.
This is by no means the first time the CVS subsidiary, established in 1981 and acquired in 2015 for about $12.7 billion, has been under the federal microscope for fraud.
In the May 16, 2017 suit, the government accused Omnicare of designing an automated label verification system that purposefully inflated profits by submitting claims for generic drugs different than those given to patients. CVS said that all happened before it acquired Omnicare.
Omnicare provides pharmacy benefits for post-acute care and senior living care, including in skilled nursing facilities, hospitals and health systems and assisted living communities.
Despite the lucrative market in an aging U.S. population with complicated drug needs, Omnicare is an underperforming business in otherwise healthy times for CVS. The unit triggered a $2.2 billion goodwill impairment charge following a late 2018 test, according to CVS’ fourth quarter filing last year.
Omnicare operates 160 pharmacies in 47 states. During the eight years under investigation, Omnicare submitted more than 35 million claims for drugs dispensed to Medicare beneficiaries in assisted living facilities alone, DOJ says.

Walgreens is inviting outside providers to deliver medical services to its pharmacies as it tries to move away from in-store clinics, the Wall Street Journal reports.
The big picture: The drugstore chain’s decision signals a shift from treating minor issues to treating chronic conditions such as diabetes, heart disease and hypertension.